Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Target Price at $36.67

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned an average recommendation of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $36.50.

Several equities analysts recently weighed in on the company. HC Wainwright cut their price objective on Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research report on Monday. Wedbush reissued an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a report on Thursday, March 27th.

Bicara Therapeutics Stock Up 11.0 %

BCAX stock opened at $10.40 on Friday. The firm’s 50-day simple moving average is $12.84 and its 200 day simple moving average is $17.03. Bicara Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). As a group, analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $582,000. FMR LLC bought a new position in Bicara Therapeutics during the third quarter worth $57,913,000. Walleye Capital LLC bought a new position in shares of Bicara Therapeutics in the third quarter valued at about $809,000. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth about $30,329,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $9,474,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.